Sun Ok Jang

Title: The Innovative Contributions of Sun Ok Jang

Introduction

Sun Ok Jang is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic solutions for cervical cancer. His work focuses on innovative approaches to combat human papillomavirus (HPV) related diseases.

Latest Patents

Sun Ok Jang holds a patent for a "Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein." This invention relates to a chimeric recombinant protein that has therapeutic effects on cervical cancer. It involves the fusion of genetically modified E6 and E7 proteins, which are known to induce carcinogenesis in HPV high-risk group type 16. The chimeric recombinant protein, when fused with a flagellin fusion protein, demonstrated a significant reduction in tumor cell volume and an enhanced immune response from specific T cells. The findings indicate that this recombinant antigen can be utilized for tumor treatment and prophylaxis, potentially serving as a therapeutic or prophylactic vaccine composition.

Career Highlights

Sun Ok Jang is associated with Genematrix Inc., where he continues to advance his research and development efforts. His work has been pivotal in exploring new avenues for cancer treatment, particularly through innovative recombinant protein technologies.

Collaborations

He collaborates with notable colleagues, including Soo Ok Kim and Suk Joon Kim, who contribute to his research endeavors and help in the advancement of their shared goals in biotechnology.

Conclusion

Sun Ok Jang's innovative work in the field of biotechnology, particularly in developing therapeutic solutions for cervical cancer, showcases his commitment to advancing medical science. His contributions through patents and collaborations highlight the importance of innovation in addressing critical health challenges.